Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients

被引:13
作者
Kim, Irene K. [1 ]
Choi, Jua [1 ]
Vo, Ashley A. [1 ]
Kang, Alexis [1 ]
Patel, Mitasha [1 ]
Toyoda, Mieko [1 ]
Mirocha, James [2 ]
Kamil, Elaine S. [1 ]
Cohen, J. Louis [1 ]
Louie, Sabrina [1 ]
Galera, Odette [1 ]
Jordan, Stanley C. [1 ]
Puliyanda, Dechu P. [1 ]
机构
[1] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, 8900 Beverly Blvd, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Biostat Core, Los Angeles, CA 90048 USA
关键词
ANTIBODY-MEDIATED REJECTION; KIDNEY-TRANSPLANTATION; TACROLIMUS MONOTHERAPY; INTRAVENOUS IMMUNOGLOBULIN; ALLOGRAFT PATHOLOGY; RANDOMIZED-TRIAL; DESENSITIZATION; RITUXIMAB; CAMPATH-1H; CLASSIFICATION;
D O I
10.1097/TP.0000000000001416
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well tolerated in pediatric renal transplantation.We report on the use of alemtuzumab induction in highly HLA sensitized (HS) pediatric kidney transplant patients. Methods. Fifty pediatric renal transplants were performed from 1/2009-12/2014. 15 HS patients received IVIG (2 g/kg x 2 doses)/rituximab (375 mg/m(2) x 1) for desensitization with alemtuzumab induction (15-30 mg, 1 dose, subcutaneous), whereas 35 nonsensitized patients received anti-IL-2R. Graft survival and infections were compared between 2 groups. Results. All HS patients had received a prior transplant and were older with lower risk for viral infections due to serostatus. Patient survival was 100%, and graft outcomes were similar with mean 1-year creatinine of 1.03 +/- 0.45 versus 0.99 +/- 0.6 (P = 0.48). Although a higher incidence of acute cellular rejection was seen in HS patients receiving alemtuzumab (P = 0.001), there was a nonsignificant difference in antibody-mediated rejection. White blood cell and absolute lymphocyte count were significantly lower in alemtuzumab group at 30 days (P < 0.0001) and at 1 year (P = 0.026 and P = 0.001), respectively. There was no significant difference in bacterial, viral, or fungal infections after transplant. Conclusions. Alemtuzumab induction with desensitization led to nearly equivalent graft survival and functional outcomes in HS pediatric patients as nonsensitized patients receiving anti-IL-2R induction. With this small sample size, we observed significant reduction of white blood cell and absolute lymphocyte count up to 1 year posttransplant. The risk of infection was comparable between the 2 groups; however, patients who received alemtuzumab were older and at lower risk of viral infection due to serostatus.
引用
收藏
页码:883 / 889
页数:7
相关论文
共 31 条
  • [1] Campath-1H use in pediatric renal transplantation
    Bartosh, SM
    Knechtle, SJ
    Sollinger, HW
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) : 1569 - 1573
  • [2] Kidney Transplantation With Minimized Maintenance: Alemtuzumab Induction With Tacrolimus Monotherapy-An Open Label, Randomized Trial
    Chan, Kakit
    Taube, David
    Roufosse, Candice
    Cook, Terence
    Brookes, Paul
    Goodall, Dawn
    Galliford, Jack
    Cairns, Tom
    Dorling, Anthony
    Duncan, Neill
    Hakim, Nadey
    Palmer, Andrew
    Papalois, Vassilios
    Warrens, Anthony N.
    Willicombe, Michelle
    McLean, Adam G.
    [J]. TRANSPLANTATION, 2011, 92 (07) : 774 - 780
  • [3] Immune Profile of Pediatric Renal Transplant Recipients following Alemtuzumab Induction
    De Serres, Sacha A.
    Mfarrej, Bechara G.
    Magee, Ciara N.
    Benitez, Fanny
    Ashoor, Isa
    Sayegh, Mohamed H.
    Harmon, William E.
    Najafian, Nader
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (01): : 174 - 182
  • [4] Alemtuzumab induction therapy in solid organ transplantation
    Friend, Peter J.
    [J]. TRANSPLANTATION RESEARCH, 2013, 2
  • [5] Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab
    Ge, Shili
    Pao, Andy
    Vo, Ashley
    Deer, Nathan
    Karasyov, Artur
    Petrosyan, Anna
    Kahwaji, Joseph
    Lukovsky, Marina
    Chai, Ning-Ning
    Aguiluz, Angela
    Mirocha, James
    Jordan, Stanley C.
    Toyoda, Mieko
    [J]. TRANSPLANT IMMUNOLOGY, 2011, 24 (03) : 142 - 148
  • [6] Survival Advantage of Pediatric Recipients of a First Kidney Transplant Among Children Awaiting Kidney Transplantation
    Gillen, D. L.
    Stehman-Breen, C. O.
    Smith, J. M.
    McDonald, R. A.
    Warady, B. A.
    Brandt, J. R.
    Wong, C. S.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (12) : 2600 - 2606
  • [7] Alemtuzumab Induction in Renal Transplantation
    Hanaway, Michael J.
    Woodle, E. Steve
    Mulgaonkar, Shamkant
    Peddi, V. Ram
    Kaufman, Dixon B.
    First, M. Roy
    Croy, Richard
    Holman, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (20) : 1909 - 1919
  • [8] Evaluation of intravenous immunoglobulin as are agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIHIG02 trial
    Jordan, SC
    Tyan, D
    Stablein, D
    Mcintosh, M
    Rose, S
    Vo, A
    Toyoda, M
    Davis, C
    Shapiro, R
    Adey, D
    Milliner, D
    Graff, R
    Steiner, R
    Ciancio, G
    Sahney, S
    Light, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12): : 3256 - 3262
  • [9] Alemtuzumab induction in pediatric kidney transplantation
    Kaabak, Michael M.
    Babenko, Nadezda N.
    Samsonov, Dmitry V.
    Sandrikov, Valery A.
    Maschan, Alexey A.
    Zokoev, Alan K.
    [J]. PEDIATRIC TRANSPLANTATION, 2013, 17 (02) : 168 - 178
  • [10] Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin
    Kahwaji, Joseph
    Sinha, Aditi
    Toyoda, Mieko
    Ge, Shili
    Reinsmoen, Nancy
    Cao, Kai
    Lai, Chih-Hung
    Villicana, Rafael
    Peng, Alice
    Jordan, Stanley
    Vo, Ashley
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (12): : 2894 - 2900